Compare HSIC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSIC | CYTK |
|---|---|---|
| Founded | 1932 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.0B |
| IPO Year | 1995 | 2004 |
| Metric | HSIC | CYTK |
|---|---|---|
| Price | $79.92 | $62.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $75.92 | ★ $82.38 |
| AVG Volume (30 Days) | 1.2M | ★ 2.2M |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.70 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $12,938,000,000.00 | $87,211,000.00 |
| Revenue This Year | $5.34 | $339.72 |
| Revenue Next Year | $3.42 | $79.08 |
| P/E Ratio | $25.24 | ★ N/A |
| Revenue Growth | 3.51 | ★ 2609.26 |
| 52 Week Low | $60.56 | $29.31 |
| 52 Week High | $82.49 | $70.98 |
| Indicator | HSIC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 47.75 |
| Support Level | $74.90 | $60.30 |
| Resistance Level | $80.03 | $65.08 |
| Average True Range (ATR) | 1.91 | 2.91 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 96.48 | 45.74 |
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.